Diabetes and treatment of chronic heart failure in a large real-world heart failure population.
Sumant P RadhoeJesse F VeenisGerard C M LinssenChris van der LeeLuc W M EurlingsHans KragtenNadea Y Y Al-WindyAukje van der SpankStefan KoudstaalHans-Peter Brunner-La RoccaJasper J BrugtsPublished in: ESC heart failure (2021)
In this large real-world HF registry, a high prevalence of DM was observed and diabetics more often received guideline-recommended target doses. Based on current evidence, the majority of patients would fulfil the enrichment criteria of SGLT2 trials in HF and the impact of this new drug class will be large.